By Chris Matheus
2024 Year-End Review
As we close out 2024, we look back and note the adjustments and enhancements we have made to our network of clinical research services in support of clinical trials efficiency. This year has been a testament to the power of persistence and commitment to our mission. We’re proud to share some of the highlights and milestones that have shaped our journey over the past 12 months.
Expanding Our Reach and Impact
In 2024, GLSA significantly expanded our global footprint. Through our growing network of partners and alliances, we were able to bridge critical gaps in patient identification and recruitment, particularly in underrepresented and diverse populations. These efforts have contributed to a more inclusive approach to clinical research, ensuring that trial outcomes better reflect the diverse world we serve.
A pivotal achievement this year was our inclusion in a pharmaceutical company request for information regarding patient recruitment capabilities. This indicates to us that our social media strategy is working. As people become aware of our offerings, we are seen as a valuable service. We now have over 100 Global Network Partners with more joining in 2025.
Advancing Innovation in Patient Recruitment
Innovation has always been at the heart of GLSA’s operations, and 2024 was no exception. Leveraging data-driven strategies and cutting-edge technology, we launched new programs designed to streamline the recruitment process while enhancing the patient experience. By embracing tools, such as AI and Machine Learning that help ensure potential subjects meet the inclusion/exclusion criteria. This is showing significant progress in reducing recruitment timelines and improving trial retention rates.
Empowering the Next Generation
One of the most fulfilling aspects of our work this year has been our efforts to nurture future leaders in the life sciences field. The GLSA Internship Program, spearheaded by co-founder Denise McNerney, has provided aspiring professionals with hands-on experience and mentorship opportunities. From building strategic initiatives to supporting patient engagement campaigns, our interns have played an integral role in advancing GLSA’s mission.
Along with our core team, we would like to extend a special acknowledgment of our new GLSA Team Members, Aspen Buck, Clinical Solutions Manager, who has excelled while successfully earning her degree in Healthcare Administration and to Dylan Grierson for his commitment to streamlining GLSA’s technology.
Thought Leadership and Advocacy
This year, GLSA’s leaders have been at the forefront of discussions shaping the future of clinical trials. Denise McNerney’s presentation at the HBA (Healthcare Businesswomen’s Association) and her participation in a webinar on the role of clinical trials and patient participation highlighted GLSA’s commitment to driving meaningful dialogue on industry challenges. Additionally, we’ve supported the founding of Women of Life Sciences, a LinkedIn Group (https://www.linkedin.com/groups/12867182/) that meets monthly. The group focuses on networking and supporting women in career planning.
These engagements have solidified GLSA’s reputation as a thought leader in the clinical research space, advocating for strategies that prioritize diversity, inclusion, and patient empowerment.
Looking Ahead to 2025
As we look toward 2025, our focus will remain on driving innovation and expanding our reach to address the evolving needs of the global clinical trials industry. Key priorities include enhancing our technological capabilities, deepening our commitment to patient engagement, and fostering new partnerships that amplify our mission. We will be expanding our focus on making the network into a community relying on each other for solutions and support.
Gratitude and Closing Thoughts
None of these achievements would have been possible without the unwavering support of our Network Partners, clients, and dedicated team members. As co-founders, Denise and I are deeply grateful for your trust and collaboration in making 2024 a year of extraordinary progress.
Together, we are shaping a future where clinical trials are accessible, inclusive, and impactful for patients around the globe. Here’s to continuing this journey of innovation and excellence in 2025 and beyond.
Warm regards,
Chris Matheus
Denise McNerney
Co-Founders, Global Life Sciences Alliance